ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Cincinnati, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Cincinnati, OH, USA:

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: revumenib
Drug: cobicistat

Phase 1, Phase 2

Syndax Pharmaceuticals
Syndax Pharmaceuticals

Cincinnati, Ohio, United States and 47 other locations

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Gilteritinib
Drug: Daunorubicin

Phase 2

PrECOG

Cincinnati, Ohio, United States and 43 other locations

chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...

Active, not recruiting
Leukemia
Drug: Methotrexate
Drug: Thioguanine

Phase 2

Incyte
Incyte

Cincinnati, Ohio, United States and 110 other locations

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs....

Enrolling
Myeloid Leukemia, Philadelphia Positive
Drug: Asciminib Adult formulation group
Drug: Asciminib Pediatric formulation group

Phase 1, Phase 2

Novartis
Novartis

Cincinnati, Ohio, United States and 34 other locations

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared wi...

Active, not recruiting
Leukemia, Myeloid, Acute
Leukemia, Myelomonocytic, Chronic
Drug: Pevonedistat
Drug: Azacitidine

Phase 3

Takeda
Takeda

Cincinnati, Ohio, United States and 240 other locations

of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia...

Enrolling
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Drug: Nilotinib
Drug: Asciminib

Phase 3

Novartis
Novartis

Cincinnati, Ohio, United States and 134 other locations

of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed ...

Active, not recruiting
Acute Myeloid Leukemia
Drug: TL-895
Drug: KRT-232

Phase 1, Phase 2

Telios Pharma

Cincinnati, Ohio, United States and 34 other locations

chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A rearrangement, KMT2A amplification, NPM1c, or...

Active, not recruiting
Acute Lymphocytic Leukemia
Mixed Phenotype Acute Leukemia
Drug: Revumenib
Drug: Chemotherapy Regimen 2

Phase 1

Syndax Pharmaceuticals
Syndax Pharmaceuticals

Cincinnati, Ohio, United States and 10 other locations

and young adult participants with relapsed/refractory acute leukemia harboring histone-lysine N-methyltransferase 2A1 (\[KMT2A1\], nucleopho...

Begins enrollment in a year or more
Acute Leukemia of Ambiguous Lineage
Acute Leukemias
Drug: Cytarabine
Drug: Dexamethasone

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Cincinnati, Ohio, United States and 11 other locations

This study will be a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had a...

Active, not recruiting
Chronic Myelogenous Leukemia - Chronic Phase
Drug: ABL001

Phase 3

Novartis
Novartis

Cincinnati, Ohio, United States and 22 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems